GlassScriptPhysician profile
Arthur Thomas Armstrong
NPI 1548234677
$43,636.31
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $16K · 2021: $10K · 2022: $3,650.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $17,490.95 | 2019-2022 | |
| Glaxosmithkline, LLC. | $13,396.09 | 2019-2022 | |
| Amgen INC. | $2,101.36 | 2019-2022 | |
| Janssen Biotech, INC. | $1,555.51 | 2019-2022 | |
| Abbvie INC. | $1,528.70 | 2019-2022 | |
| Ucb, INC. | $1,065.53 | 2019-2022 | |
| Pfizer INC. | $1,022.96 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $977.23 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $974.88 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $657.52 | 2019-2022 | |
| Genentech USA, INC. | $634.11 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $371.51 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $332.11 | 2021-2022 | |
| Celgene Corporation | $258.51 | 2019 | |
| Aurinia Pharma U.S., INC. | $252.94 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $220.66 | 2019-2020 | |
| Zyla Life Sciences, INC. | $209.94 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $156.99 | 2022 | |
| Lilly USA, LLC | $149.45 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $78.34 | 2019-2022 | |
| Radius Health, INC. | $65.72 | 2020-2021 | |
| Ibsa Pharma INC. | $44.06 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $37.19 | 2022 | |
| Organon LLC | $26.46 | 2021-2022 | |
| Genzyme Corporation | $15.19 | 2020 | |
| Sobi, INC | $12.40 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.